{
  "ProtocolSection": {
    "IdentificationModule": {
      "NCTId": "NCT01649687",
      "OrgStudyIdInfo": {
        "OrgStudyId": "SB-VGH-201001"
      },
      "Organization": {
        "OrgFullName": "National Yang Ming University",
        "OrgClass": "OTHER"
      },
      "BriefTitle": "Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells",
      "OfficialTitle": "Treatment of Cerebellar Ataxia With Mesenchymal Stem Cells"
    },
    "StatusModule": {
      "StatusVerifiedDate": "September 2014",
      "OverallStatus": "Completed",
      "ExpandedAccessInfo": {
        "HasExpandedAccess": "No"
      },
      "StartDateStruct": {
        "StartDate": "May 2012"
      },
      "PrimaryCompletionDateStruct": {
        "PrimaryCompletionDate": "January 2014",
        "PrimaryCompletionDateType": "Actual"
      },
      "CompletionDateStruct": {
        "CompletionDate": "January 2014",
        "CompletionDateType": "Actual"
      },
      "StudyFirstSubmitDate": "April 10, 2012",
      "StudyFirstSubmitQCDate": "July 22, 2012",
      "StudyFirstPostDateStruct": {
        "StudyFirstPostDate": "July 25, 2012",
        "StudyFirstPostDateType": "Estimate"
      },
      "LastUpdateSubmitDate": "September 11, 2014",
      "LastUpdatePostDateStruct": {
        "LastUpdatePostDate": "September 12, 2014",
        "LastUpdatePostDateType": "Estimate"
      }
    },
    "SponsorCollaboratorsModule": {
      "ResponsibleParty": {
        "ResponsiblePartyType": "Principal Investigator",
        "ResponsiblePartyInvestigatorFullName": "Oscar Kuang-Sheng Lee",
        "ResponsiblePartyInvestigatorTitle": "Director of Stem Cell Research Centre",
        "ResponsiblePartyInvestigatorAffiliation": "National Yang Ming University"
      },
      "LeadSponsor": {
        "LeadSponsorName": "National Yang Ming University",
        "LeadSponsorClass": "OTHER"
      }
    },
    "OversightModule": {
      "OversightHasDMC": "Yes"
    },
    "DescriptionModule": {
      "BriefSummary": "The study is to investigate the efficacy and safety of allogenous transplantation of adipose-derived mesenchyma stem cells in patients with cerebellar ataxia."
    },
    "ConditionsModule": {
      "ConditionList": {
        "Condition": [
          "Cerebellar Ataxia"
        ]
      }
    },
    "DesignModule": {
      "StudyType": "Interventional",
      "PhaseList": {
        "Phase": [
          "Phase 1",
          "Phase 2"
        ]
      },
      "DesignInfo": {
        "DesignAllocation": "N/A",
        "DesignInterventionModel": "Single Group Assignment",
        "DesignPrimaryPurpose": "Treatment",
        "DesignMaskingInfo": {
          "DesignMasking": "None (Open Label)"
        }
      },
      "EnrollmentInfo": {
        "EnrollmentCount": "7",
        "EnrollmentType": "Actual"
      }
    },
    "ArmsInterventionsModule": {
      "ArmGroupList": {
        "ArmGroup": [
          {
            "ArmGroupLabel": "Mesenchymal stem cells(MSC) treatment",
            "ArmGroupType": "Experimental",
            "ArmGroupDescription": "All subjects will receive allogeneic adult adipose-derived mesenchymal stem cells",
            "ArmGroupInterventionList": {
              "ArmGroupInterventionName": [
                "Biological: Allogeneic adult adipose-derived mesenchymal stem cells"
              ]
            }
          }
        ]
      },
      "InterventionList": {
        "Intervention": [
          {
            "InterventionType": "Biological",
            "InterventionName": "Allogeneic adult adipose-derived mesenchymal stem cells",
            "InterventionDescription": "Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells",
            "InterventionArmGroupLabelList": {
              "InterventionArmGroupLabel": [
                "Mesenchymal stem cells(MSC) treatment"
              ]
            }
          }
        ]
      }
    },
    "OutcomesModule": {
      "PrimaryOutcomeList": {
        "PrimaryOutcome": [
          {
            "PrimaryOutcomeMeasure": "Safety evaluation",
            "PrimaryOutcomeDescription": "Safety evaluate through vital signs, the results of clinical lab tests and adverse events (AEs)",
            "PrimaryOutcomeTimeFrame": "12 months"
          }
        ]
      },
      "SecondaryOutcomeList": {
        "SecondaryOutcome": [
          {
            "SecondaryOutcomeMeasure": "Alterations in SARA score",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Positron emission tomography",
            "SecondaryOutcomeDescription": "18F-FDG used for the assessment of glucose metabolism in the brain",
            "SecondaryOutcomeTimeFrame": "9 months"
          },
          {
            "SecondaryOutcomeMeasure": "Magnetic resonance spectroscopy",
            "SecondaryOutcomeDescription": "NAA/Cr,Cho/Cr,NAA/Cho ratios to reflect neuronal/cerebral white mater integrity",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Assessment of language and swallowing functions",
            "SecondaryOutcomeDescription": "changes in levels of severity: normal/slight/mild/moderate/severe",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Evaluation of syncope",
            "SecondaryOutcomeDescription": "Tilt table test",
            "SecondaryOutcomeTimeFrame": "12 months"
          },
          {
            "SecondaryOutcomeMeasure": "Balance test",
            "SecondaryOutcomeTimeFrame": "12 months"
          }
        ]
      }
    },
    "EligibilityModule": {
      "EligibilityCriteria": "Inclusion Criteria:\n\nPatients diagnosed of spinocerebellar ataxia 3 (SCA3) or multiple system atrophy-cerebellar (MSA-C).\nSubject's SARA score at 10~20 points.\nAges between 20~70 years.\nSigned informed consent from the patient and/or guardian.\n\nExclusion Criteria:\n\nSubjects enrolled in any other cell therapy studies within the past 30 days.\nPregnancy test positive.\nSubjects deemed to be not suitable for the study by the investigator.",
      "HealthyVolunteers": "No",
      "Gender": "All",
      "MinimumAge": "20 Years",
      "MaximumAge": "70 Years",
      "StdAgeList": {
        "StdAge": [
          "Adult",
          "Older Adult"
        ]
      }
    },
    "ContactsLocationsModule": {
      "LocationList": {
        "Location": [
          {
            "LocationFacility": "Taipei Veterans General Hospital",
            "LocationCity": "Taipei",
            "LocationCountry": "Taiwan"
          }
        ]
      }
    }
  },
  "DerivedSection": {
    "MiscInfoModule": {
      "VersionHolder": "January 20, 2022"
    },
    "ConditionBrowseModule": {
      "ConditionMeshList": {
        "ConditionMesh": [
          {
            "ConditionMeshId": "D000001259",
            "ConditionMeshTerm": "Ataxia"
          },
          {
            "ConditionMeshId": "D000002524",
            "ConditionMeshTerm": "Cerebellar Ataxia"
          }
        ]
      },
      "ConditionAncestorList": {
        "ConditionAncestor": [
          {
            "ConditionAncestorId": "D000020820",
            "ConditionAncestorTerm": "Dyskinesias"
          },
          {
            "ConditionAncestorId": "D000009461",
            "ConditionAncestorTerm": "Neurologic Manifestations"
          },
          {
            "ConditionAncestorId": "D000009422",
            "ConditionAncestorTerm": "Nervous System Diseases"
          },
          {
            "ConditionAncestorId": "D000002526",
            "ConditionAncestorTerm": "Cerebellar Diseases"
          },
          {
            "ConditionAncestorId": "D000001927",
            "ConditionAncestorTerm": "Brain Diseases"
          },
          {
            "ConditionAncestorId": "D000002493",
            "ConditionAncestorTerm": "Central Nervous System Diseases"
          }
        ]
      },
      "ConditionBrowseLeafList": {
        "ConditionBrowseLeaf": [
          {
            "ConditionBrowseLeafId": "M3717",
            "ConditionBrowseLeafName": "Ataxia",
            "ConditionBrowseLeafAsFound": "Cerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M4925",
            "ConditionBrowseLeafName": "Cerebellar Ataxia",
            "ConditionBrowseLeafAsFound": "Cerebellar Ataxia",
            "ConditionBrowseLeafRelevance": "high"
          },
          {
            "ConditionBrowseLeafId": "M21727",
            "ConditionBrowseLeafName": "Dyskinesias",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M11556",
            "ConditionBrowseLeafName": "Neurologic Manifestations",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4927",
            "ConditionBrowseLeafName": "Cerebellar Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4356",
            "ConditionBrowseLeafName": "Brain Diseases",
            "ConditionBrowseLeafRelevance": "low"
          },
          {
            "ConditionBrowseLeafId": "M4894",
            "ConditionBrowseLeafName": "Central Nervous System Diseases",
            "ConditionBrowseLeafRelevance": "low"
          }
        ]
      },
      "ConditionBrowseBranchList": {
        "ConditionBrowseBranch": [
          {
            "ConditionBrowseBranchAbbrev": "BC10",
            "ConditionBrowseBranchName": "Nervous System Diseases"
          },
          {
            "ConditionBrowseBranchAbbrev": "BC23",
            "ConditionBrowseBranchName": "Symptoms and General Pathology"
          },
          {
            "ConditionBrowseBranchAbbrev": "All",
            "ConditionBrowseBranchName": "All Conditions"
          }
        ]
      }
    }
  }
}